In late September Skinvisible announced the European Patent Office (EPO) issued a Notice of Intent to Grant European patent application number 02752847.0 pertaining to Skinvisible’s drug delivery system, Invisicare, which is a drug delivery technology used in prescription, over-the-counter and cosmeceutical products. The comprehensive patent protects Invisicare® composition , method of combining polymers to make the Invisicare complex and the skin / medical conditions Invisicare is used for. This patent provides protection with claims that were also patented in the other Invisicare international patents. This patent approval is a significant milestone for Skinvisible as multi-national pharmaceutical and consumer goods companies seeking products for global distribution will now have protected products to license from Skinvisible on four continents, covering over twenty-two countries. Invisicare patent coverage now includes Europe, plus previously announced India, Australia, China, Japan, Hong Kong, Korea, Canada and the USA. Skinvisible continues to proactively build and strengthen its global intellectual property portfolio with twenty-eight patents pending. All patents with Invisicare® are owned by Skinvisible.
Skinvisible Pharmaceuticals is a research-and-development company that licenses its proprietary formulations made with Invisicare®, its patented polymer delivery system that offers life-cycle management and unique enhancements for topically delivered products. Invisicare® holds active ingredients on the skin for extended periods of time resisting both wash off and perspiration along with controlling the release of actives and reducing irritation. Skinvisible receives a combination of research and development fees, upfront license fees, and ongoing royalties for the life of the Invisicare® patent. Skinvisible's value lies in its ability to continually generate new IP (Intellectual. Property) on dermatology and medical products formulated with Invisicare®. This month the company announced that its DermSafe(R) Hand Sanitizing Lotion has received the "Seal of Approval" from the Dermatology Review Panel(TM) ("DRP"). DRP is an independent panel of dermatologists that reviews scientific data for non-prescription products in order to authenticate a product's claims. DRP dermatologists evaluated Skinvisible's scientific data and validated the following claims for DermSafe Hand Sanitizer: DermSafe is alcohol-free, it offers protection from harmful bacteria, it resists wash-off and it provides a moisture barrier for the hands. DermSafe, marketed by Alto Pharmaceuticals in Canada, will soon display the DRP Seal on its promotional materials and packaging.
In July Skinvisible announced that its licensee, Women's Choice Pharmaceuticals LLC, a specialty pharmaceutical company based in Gilbert, Arizona, launched ProCort(R), Skinvisible's first prescription product in the United States. ProCort(R) is a topical treatment for hemorrhoids formulated with Skinvisible's patented polymer delivery system Invisicare(R). Invisicare enhances the delivery of active ingredients by controlling the release and provides superior binding properties. ProCort(R) is made of a combination of hydrocortisone acetate and pramoxine hydrochloride.
What is AQUAPRIN™ ? In development since 1993 with over $3 million invested to-date, Aquaprin™ is a liquid derivative of aspirin based on a patent-pending formula. The product is designed to dissolve nearly instantly in just 1.5 ounces of water, which can be absorbed into the bloodstream up to 10 times faster than traditional OTC pain relievers, and with little to no stomach upset.Mr Phykitt will provide insight into the development of Aquaprin., He has extensive experience in the design and implementation of pharmaceutical manufacturing products. Working with companies such as Monsanto, Warner-Lambert, Durkee Foods, Johnson & Johnson (McNeil), American Home Products and many other pharmaceutical companies, Mr. Phykitt has been tabbed with the bringing a litany of current name brand products to full production. Pharmstar has completed all patenting of AQUAPRIN™ and the necessary protection of its intellectual property. Research and development of AQUAPRIN™ has been completed, and the company is preparing a full scale production facility for retail marketing in 2012.
Tues Oct 25th , Howard Phykitt, CEO PharmStar Pharmaceuticals, Inc. PHAR; Mr. Phykitt is the inventor AQUAPRIN™ and Andrew Lai, CFO Lucas Energy LEI http://www.lucasenergy.com
Tues Oct 25th Andrew Lai, CFO Lucas Energy LEI http://www.lucasenergy.com Lucas Energy, Inc. (NYSE Amex: LEI) is an Independent oil & gas company with oil properties in the Austin Chalk and Eagle Ford Shale.
Lucas Energy (LEI) resources could be significant. Lucas directly benefited from Marathon's (MRO) purchase of Hilcorp. Since July the Company has been meeting with investment banking groups to discuss various possible future plans concerning its Eagle Ford acres. Lucas is considering the different alternatives, including but not limited to converting the position to cash and focusing on the development of the Austin Chalk reserves.
Mr. Lai has over 20 years of corporate and financial experience primarily in the exploration and production sector of the oil and gas energy industry, with specialization in the finance, legal and administrative functions.
Mr. Lai served as Chief Financial Officer with Far East Energy Corporation (“Far East”), held various managerial positions with EOG Resources, Inc. and held various positions with UMC Petroleum Corp. (which subsequently merged into Devon Energy). Mr. Lai received from the University of Houston his Bachelor of Business Administration in 1987, Master of Business Administration in 1991, and Juris Doctorate in 2004. Mr. Lai is a Texas certified public accountant and attorney and holds memberships at the State Bar of Texas, the American Bar Association and the American Institute of Certified Public Account.
Thur Oct 20 Investment Strategies for Stocks Forex Market and Economic Analysis Erick Siffert COO RYUN
(Part 1)
Thur Oct 20 Investment Strategies for Stocks Forex, Metals. Market and Economic Analysis and Erick Siffert COO RYUN
Respect Your Universe, Inc.is a a premium performance apparel and equipment company rooted in and inspired by Mixed Martial Arts. Focused on the needs of the athlete, RYU brings innovative design, development and production of premium authentic performance gear with style to mixed martial artists and athlete enthusiasts worldwide. The RYU brand is based on respect, honor and sustainability. Respect Your Universe, Inc. was founded in 2008 and is based in Las Vegas, Nevada. The Company has moved past the development stage; In August RYU launched its online Web store and placed their first product order for the debut of their spring 2012 premium high performance line. This month RYU was profiled on the front page of the Portland Business Journal Oct 14 2011 Issue after making their runway debut at Portland Fashion Week on October 6th 2011 as one of the leading designers in athletic-wear to showcase their Spring 2012 Men's High Performance Line.
Erick Siffert – COO previously served as Director of Product Operations at lululemon athletica where he devised and implemented protocols and business practices in the areas of sourcing and product development for an Internationally recognized company. His vision, dedication, and drive was an integral part of the success story that has become lululemon. Mr. Siffert also served for over 19 years at Nike Inc. where he developed global sourcing strategies for the Nike Outdoor and Global All Conditions Gear divisions. Mr. Siffert also managed the Nike European Liaison Office and was instrumental in helping open and expand sourcing throughout Europe with great success.
Protokinetix. is a biotechnology company that as developed and patented a family of synthetic anti-aging glycopeptides (AAGP™) for medicine and the biotechnology and cosmetic industries. Protokinetix engages in the R & D of anti-aging glycopeptides (AAGPs™) for enhancing the health and extending the life of biologically sensitive cells
Tuesday October 18, 2011; Ross Senior , CEO PKTX Get Investment Strategies for Stocks , Forex and Metals. Market and Economic Analysis and News.
Last month the company received Excellent Results from a University of British Columbia Eye inflammation Study. Which opens up entirely new potential applications for AAGP’s™. In August, Protokinetix completed a sale of AAGP’™ as a vital tool to protect delicate cells in the process of utilizing stem cells. In May Protokinetix entered into a Joint Venture Agreement with Imaginative Research Associates, Inc. to formulate a topical anti-inflammation product for the skin care market. Over the last 23-years Imaginative Research Associates, Inc. has successfully partnered with several large pharmaceutical dermatology and cosmetic companies and has licensed out patents and know-how to launch many leading products in the skin care arena. ProtoKinetix Inc. 225 Folkestone Way West Vancouver, BC V7S 2Y6 Phone: 604-926-6627 Fax: 604-926-6632 Website: http://www.protokinetix.com
Thursday October 13th Special Guest: Andrew Lai, CFO Lucas Energy LEI http://www.lucasenergy.com Lucas Energy, Inc. (NYSE Amex: LEI) is an Independent oil & gas company with oil properties in the Austin Chalk and Eagle Ford Shale. Lucas Energy (LEI) resources could be significant. Lucas directly benefited from Marathon's (MRO) purchase of Hilcorp. Since July the Company has been meeting with investment banking groups to discuss various possible future plans concerning its Eagle Ford acres. Lucas is considering the different alternatives, including but not limited to converting the position to cash and focusing on the development of the Austin Chalk reserves.
Thursday October 13, 2011 Andrew Lai, CFO Lucas Energy LEI http://www.lucasenergy.com Get Investment Strategies for Stocks , Forex and Metals Market and Economic Analysis – News.
Mr. Lai has over 20 years of corporate and financial experience primarily in the exploration and production sector of the oil and gas energy industry, with specialization in the finance, legal and administrative functions. Mr. Lai served as Chief Financial Officer with Far East Energy Corporation (“Far East”), held various managerial positions with EOG Resources, Inc. and held various positions with UMC Petroleum Corp. (which subsequently merged into Devon Energy). Mr. Lai received from the University of Houston his Bachelor of Business Administration in 1987, Master of Business Administration in 1991, and Juris Doctorate in 2004. Mr. Lai is a Texas certified public accountant and attorney and holds memberships at the State Bar of Texas, the American Bar Association and the American Institute of Certified Public Account.
Skinvisible Pharmaceuticals is a research-and-development company that licenses its proprietary formulations made with Invisicare®, its patented polymer delivery system that offers life-cycle management and unique enhancements for topically delivered products. Invisicare® holds active ingredients on the skin for extended periods of time resisting both wash off and perspiration along with controlling the release of actives and reducing irritation. Skinvisible receives a combination of research and development fees, upfront license fees, and ongoing royalties for the life of the Invisicare® patent.
Skinvisible's value as an Investment strategy lies in its ability to continually generate new IP (Intellectual. Property) on dermatology and medical products formulated with Invisicare®. On September 22, 2011 Skinvisible Pharmaceuticals, Inc. announced the European Patent Office (EPO) has issued a Notice of Intent to Grant European patent application number 02752847.0 pertaining to Skinvisible’s drug delivery system, Invisicare, which is a drug delivery technology used in prescription, over-the-counter and cosmeceutical products. The patent protects Invisicare® composition ,
All patents with Invisicare® are owned by Skinvisible. For more information about Skinvisible call the Bill Chippas Show at 772-236-9294
In July Skinvisible announced that its licensee, Women's Choice Pharmaceuticals LLC, a specialty pharmaceutical company based in Gilbert, Arizona, has launched ProCort(R), Skinvisible's first prescription product in the United States. ProCort(R) is a topical treatment for hemorrhoids formulated with Skinvisible's patented polymer delivery system Invisicare(R). Invisicare enhances the delivery of active ingredients by controlling the release and provides superior binding properties. ProCort(R) is made of a combination of hydrocortisone acetate and pramoxine hydrochloride. ProCort(R), launched this week, is a prescription product focused on the women's health market.
Mr. Sawyer is a proven hands-on energy executive with over 35 years of diversified experience in the energy industry with firms such as ARCO, Houston Oil & Minerals, The Superior Oil Company, and Energy Resources Company (ERCO). He founded the petroleum consulting firm of Exploitation Engineers, Inc. in 1980; The firm of Plantation Petroleum Corporation in 1981; and Lucas Energy, Inc. in 2004. As a registered professional engineer (now called a licensed professional engineer), Mr. Sawyer has provided petroleum consulting services to private investors, independent oil companies, banking institutions, major energy and chemical companies, and the US government.
Tuesday October 11, Special Guest: William Sawyer ,CEO Lucas Energy. LEIttp://www.lucasenergy.com Lucas Energy, Inc. (NYSE Amex: LEI) is an Independent oil & gas company with oil properties in the Austin Chalk and Eagle Ford Shale Lucas owns 4400 net acres in the Eagle Ford. Lucas Energy (LEI) resources could be significant. Lucas directly benefited from Marathon's (MRO) purchase of Hilcorp. Since July the Company has been meeting with investment banking groups to discuss various possible future plans concerning its 4,400 net Eagle Ford acres. With a correlative value of $95 million, based on Marathon Oil Corporation’s acquisition of the Hilcorp Eagle Ford acreage in June 2011, (about $4.20 per share fully diluted), Lucas is considering the different alternatives, including but not limited to converting the position to cash and focusing on the development of the Austin Chalk reserves.
Protokinetix. is a biotechnology company that has developed and patented a family of synthetic anti-aging glycopeptides (AAGP™) for medicine and the biotechnology and cosmetic industries. Protokinetix engages in the R & D of anti-aging glycopeptides (AAGPs™) for enhancing the health and extending the life of biologically sensitive cells Last month the company received Excellent Results from a University of British Columbia Eye inflammation Study. Which opens up entirely new potential applications for AAGP’s™. In August, Protokinetix completed a sale of AAGP’™ as a vital tool to protect delicate cells in the process of utilizing stem cells. In May Protokinetix entered into a Joint Venture Agreement with Imaginative Research Associates, Inc. to formulate a topical anti-inflammation product for the skin care market. Over the last 23-years Imaginative Research Associates, Inc. has successfully partnered with several large pharmaceutical dermatology and cosmetic companies and has licensed out patents and know-how to launch many leading products in the skin care arena. ProtoKinetix Inc. 225 Folkestone Way West Vancouver, BC V7S 2Y6 Phone: 604-926-6627 Fax: 604-926-6632 Website: http://www.protokinetix.com
Thur Oct 6, 2011 Ross Senior,CEO Protokinetix Plus Investment Strategies ,News and More !
Press Release Sept 21, 2011; ProtoKinetix Receives Excellent Results from the University of British Columbia Eye Inflammation Study : ProtoKinetix (PKTX) (www.protokinetix.com), is pleased to announce that it has received excellent results from the eye inflammation study conducted by UBC (University of British Columbia). The tests conducted by Dr. Gregory-Evans MD, PhD, FRCS, FRCOphth, were designed to determine whether the powerful anti-inflammatory AAGP™ molecule could be successfully delivered to inflamed areas throughout the eye. The result demonstrated that AAGP™ penetrates through the extremely protective barriers of the eye without side effects. ProtoKinetix has proven the ability of AAGP™ to protect human cells against inflammation causing agents. There are many forms of eye inflammation that are typically treated with an aggressive course of corticosteroids. Due, in part, to the short effective life of topical steroids, current treatments involve the application on an hourly basis. These powerful drugs can lead to numerous sight threatening complications.
Dr. Gregory-Evans, a professor of Ophthalmology and Leadership Chair in Macular Research, concludes that AAGP™ penetrates the eye when topically applied as a twice a day or four times a day regimen. AAGP™ can be detected within the cornea and ciliary body. Drug was also seen to appear in retinal tissue, most convincingly when a four times a day regimen was used. These results represent a major step in the development of a potent, non-steroidal, anti-inflammatory drug. Ross L. Senior, President and CEO
Tues Oct 04; XBOR Will Gray CEO Cross Border Resources, CEO Plus Discussion on Market Techncials ,Stocks, ETFs, Forex , Eurozone, Greece and Crude Oil.
Cross Border Resources is an oil and gas company holding more than 800,000 gross (some 300,000 net) mineral and lease acres, located primarily in New Mexico. The company’s current operations focus on the prolific, multi-play/multi-pay PermianBasin, which offers Cross Border rapid-growth potential. The company seeks to become the premier, non-operated working interest owner in the Permian’s rapidly emerging, unconventional plays – in addition to participating in the basin’s well-established, conventional plays. Some 31,000 of Cross Border’s net acres lie within the PermianBasin. http://www.xbres.com
About Everett Willard Grey, II Mr. Gray is a seasoned executive who has been the company’s Chairman and CEO since December 10, 2008. He has been extensively involved in entrepreneurial ventures in oil field production as an angel investor and advisor/consultant to exploration and production start ups. Mr. Gray also has a diverse background gained from sales and marketing positions with a number of Fortune 500 companies, including Prudential Financial, Pharmacia Corp., Medtronic Inc., and Guidant Corporation
Since 2005, Treasure Coast listeners and Global Viewers have been tuning to WPSL 1590 at 6 PM on Thursday and on Tuesday at 10 AM to hear Bill’s clear concise and witty comments. Guests come from a wide range of global and local businesses. Individual investors, active traders and institutional professionals rely on Bill's timely unbiased analysis of investment strategies, deep rooted market background and experience spanning four decades to make intelligent and common sense investments. Bill's weekly Stock Market Comments appear in Weekly Market Strategies delivered by Princeton Research to global investors and Bill's opinion columns appear in Your News.com
Oct 27th 
